IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is highly heterogeneous. Here, the authors perform exome sequencing and bulk RNA sequencing on 73 tumor regions from 14 ICC patients to portray the multi‐faceted intratumor heterogeneity (ITH) landscape of ICC. The authors show that ITH is highly concordant across genomic, transcriptomic, and immune levels. Comparison of these data to 8 published datasets reveals significantly higher degrees of ITH in ICC than hepatocellular carcinoma. Remarkably, the authors find that high‐ITH tumors highly overlap with the IDH (isocitrate dehydrogenase)‐mutant subgroup ( IDH ‐SG), comprising of IDH ‐mutated tumors and IDH ‐like tumors, that is, those IDH ‐wildtype tumors that exhibit similar molecular profiles to the IDH ‐mutated ones. Furthermore, IDH ‐SG exhibits less T cell infiltration and lower T cell cytotoxicity, indicating a colder tumor microenvironment (TME). The higher ITH and colder TME of IDH ‐SG are successfully validated by single‐cell RNA sequencing on 17 503 cells from 4 patients. Collectively, the study shows that IDH mutant subgroup status, rather than IDH mutation alone, is associated with ITH and the TME of ICC tumors. The results highlight that IDH ‐like patients may also benefit from IDH targeted therapies and provide important implications for the diagnosis and treatment of ICC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In conclusion, much remains to be discovered, but cholangiocarcinoma is a highly desmoplastic and cold tumor with low immune cell infiltration and heterogeneous intratumor areas [219, 220].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Efremova, M., Vento-Tormo, M., Teichmann, S. A., & Vento-Tormo, R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0292-x · Cited by 3,449
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Research works printed but not linked: 1
- 10.1016/j.cell.2017.05.046 · DOI · Paper page
Cited by
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity
Xue, R., Zhang, Q., Cao, Q., Kong, R., Xiang, X., Liu, H., Feng, M., Wang, F., Cheng, J., Li, Z., et al. (2022) · Nature · doi:10.1038/s41586-022-05400-x · Cited by 935
Self-citationImmunology and immunotherapy of cholangiocarcinoma
Greten, T. F., Schwabe, R., Bardeesy, N., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00741-4 · Cited by 193
Yang, H., Cheng, J., Zhuang, H., Xu, H., Wang, Y., Zhang, T., Yang, Y., Qian, H.-G., Lu, Y., Han, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.004 · Cited by 187
Self-citation(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
“In conclusion, much remains to be discovered, but cholangiocarcinoma is a highly desmoplastic and cold tumor with low immune cell in fi ltration and heterogeneous intratumor areas [219, 220].”
Guo, L., Yi, X., Chen, L., Zhang, T., Guo, H., Chen, Z., Cheng, J., Cao, Q., Liu, H., Hou, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.08.052 · Cited by 86
Self-citation
Metadata
- Authors
- Xiang, X., Liu, Z., Zhang, C., Li, Z., Gao, J., Zhang, C., Cao, Q., Cheng, J., Liu, H., Chen, D., Cheng, Q., Zhang, N., Xue, R., Bai, F., & Zhu, J.
- Affiliations
- Department of Hepatobiliary Surgery, Peking University People's Hospital Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China
- Peking University (CN)
- Peking University People's Hospital (CN)
- Peking University First Hospital (CN)
- Corresponding author
- Xue, Ruidong
- Bai, Fan
- Zhu, Jiye
- ORCID
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2021-07-11
- Volume
- 8
- Issue
- 17
- Pages
- e2101230-e2101230
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC8425914
- OpenAlex
- W3182403227
- Cited by
- 71
- References
- 57
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 21 · 2023: 12 · 2022: 10 · 2021: 3
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Advanced Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- National Science and Technology Major Project (2018ZX10302205, 2019YFC1315702, 2018ZX10723204)
- National Natural Science Foundation of China (81802813, 81988101, 81972656, 81570590, 81872508)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- intrahepatic cholangiocarcinoma, intratumoral heterogeneity, IDH mutation, tumor microenvironment, T cell infiltration, T cell cytotoxicity, tumor immune microenvironment, single-cell RNA sequencing
- MeSH terms
- Bile Duct Neoplasms, Humans, Isocitrate Dehydrogenase, Mutation, Cholangiocarcinoma, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.